JP6317348B2 - 注射用組成物 - Google Patents

注射用組成物 Download PDF

Info

Publication number
JP6317348B2
JP6317348B2 JP2015524749A JP2015524749A JP6317348B2 JP 6317348 B2 JP6317348 B2 JP 6317348B2 JP 2015524749 A JP2015524749 A JP 2015524749A JP 2015524749 A JP2015524749 A JP 2015524749A JP 6317348 B2 JP6317348 B2 JP 6317348B2
Authority
JP
Japan
Prior art keywords
composition
situ
dmso
forming
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015524749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523405A (ja
Inventor
フランコ ロドリゲス ギジェルモ
フランコ ロドリゲス ギジェルモ
グティエロ アドゥリス イボン
グティエロ アドゥリス イボン
Original Assignee
ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ
ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6317348(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ, ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ filed Critical ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ
Publication of JP2015523405A publication Critical patent/JP2015523405A/ja
Application granted granted Critical
Publication of JP6317348B2 publication Critical patent/JP6317348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015524749A 2012-08-03 2013-07-29 注射用組成物 Active JP6317348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201231271A ES2390439B1 (es) 2012-08-03 2012-08-03 Composición inyectable
ESP201231271 2012-08-03
PCT/EP2013/065877 WO2014019972A1 (en) 2012-08-03 2013-07-29 Injectable compositions comprising letrozole or anastrozole

Publications (2)

Publication Number Publication Date
JP2015523405A JP2015523405A (ja) 2015-08-13
JP6317348B2 true JP6317348B2 (ja) 2018-04-25

Family

ID=47046938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524749A Active JP6317348B2 (ja) 2012-08-03 2013-07-29 注射用組成物

Country Status (31)

Country Link
EP (1) EP2879661B1 (https=)
JP (1) JP6317348B2 (https=)
KR (1) KR101892109B1 (https=)
CN (1) CN104519870B (https=)
AU (1) AU2013298705B2 (https=)
BR (1) BR112015002370B1 (https=)
CA (1) CA2880347C (https=)
CL (1) CL2015000259A1 (https=)
CY (1) CY1125157T1 (https=)
DK (1) DK2879661T3 (https=)
EA (1) EA033316B1 (https=)
ES (2) ES2390439B1 (https=)
HR (1) HRP20220537T1 (https=)
HU (1) HUE058322T2 (https=)
IL (1) IL236981B (https=)
IN (1) IN2015DN01711A (https=)
LT (1) LT2879661T (https=)
MA (1) MA37870B1 (https=)
MX (1) MX362874B (https=)
MY (1) MY194726A (https=)
NZ (1) NZ705558A (https=)
PH (1) PH12015500231B1 (https=)
PL (1) PL2879661T3 (https=)
PT (1) PT2879661T (https=)
RS (1) RS63104B1 (https=)
SG (1) SG11201500793VA (https=)
SI (1) SI2879661T1 (https=)
SM (1) SMT202200127T1 (https=)
UA (1) UA113317C2 (https=)
WO (1) WO2014019972A1 (https=)
ZA (1) ZA201501426B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CA3157003A1 (en) * 2019-10-07 2021-04-15 Oak Crest Institute Of Science Orally implantable drug delivery device
KR102319352B1 (ko) 2021-02-03 2021-10-29 바이오메디팜 어업회사법인 주식회사 첨연어의 수컷화 비율을 높이는 비호르몬적 방법
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2025153747A1 (es) * 2024-01-17 2025-07-24 Laboratorios Farmacéuticos Rovi, S.A. Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB0517673D0 (en) 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
MX2009003737A (es) * 2006-10-05 2009-06-16 Panacea Biotec Ltd Composicion inyectable en deposito y su procedimiento de preparacion.
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
PT2394663T (pt) * 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物

Also Published As

Publication number Publication date
CY1125157T1 (el) 2024-02-16
EP2879661A1 (en) 2015-06-10
IN2015DN01711A (https=) 2015-05-22
UA113317C2 (xx) 2017-01-10
BR112015002370A2 (pt) 2017-07-04
DK2879661T3 (da) 2022-04-19
EA201500196A1 (ru) 2015-05-29
PH12015500231A1 (en) 2015-04-06
WO2014019972A1 (en) 2014-02-06
PT2879661T (pt) 2022-04-06
NZ705558A (en) 2018-02-23
IL236981B (en) 2021-12-01
SI2879661T1 (sl) 2022-07-29
JP2015523405A (ja) 2015-08-13
AU2013298705B2 (en) 2018-03-08
CN104519870A (zh) 2015-04-15
EP2879661B1 (en) 2022-01-26
MX2015001513A (es) 2015-04-08
PL2879661T3 (pl) 2022-05-16
ES2390439B1 (es) 2013-09-27
HUE058322T2 (hu) 2022-07-28
EA033316B1 (ru) 2019-09-30
ES2390439A1 (es) 2012-11-13
MY194726A (en) 2022-12-15
MA37870A1 (fr) 2016-04-29
LT2879661T (lt) 2022-04-11
RS63104B1 (sr) 2022-04-29
KR101892109B1 (ko) 2018-09-28
KR20150040337A (ko) 2015-04-14
HRP20220537T1 (hr) 2022-06-10
CN104519870B (zh) 2017-09-15
CL2015000259A1 (es) 2015-06-05
SG11201500793VA (en) 2015-02-27
AU2013298705A1 (en) 2015-03-12
ZA201501426B (en) 2016-01-27
MA37870B1 (fr) 2017-01-31
BR112015002370B1 (pt) 2023-04-25
HK1204551A1 (en) 2015-11-27
ES2926715T3 (es) 2022-10-27
PH12015500231B1 (en) 2015-04-06
IL236981A0 (en) 2015-03-31
CA2880347C (en) 2021-05-04
CA2880347A1 (en) 2014-02-06
SMT202200127T1 (it) 2022-07-21
MX362874B (es) 2019-02-20

Similar Documents

Publication Publication Date Title
JP6317348B2 (ja) 注射用組成物
US11918682B2 (en) Injectable composition with aromatase inhibitor
Ju et al. Thermosensitive micelles–hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel
BR112012030686B1 (pt) Composição de implante de formação in situ injetável de retardo de risperidona e kit farmacêutico
JP2023553976A (ja) がんを治療するための材料及び方法
Asaf et al. Amphotericin B nanocrystals integrated with bilayer dissolving microneedles: a new strategy for transmucosal delivery of amphotericin B to improve the effectiveness of oral candidiasis therapy
Rencber et al. Preparation and characterization of mucoadhesive gels containing pentoxifylline loaded nanoparticles for vaginal delivery of genital ulcer
CN108703942A (zh) 载有纳米材料包裹保胎药物的微针给药系统及制备方法
RU2699674C1 (ru) Композиция для чрескожной абсорбции
EP3746047B1 (en) Injectable composition
CN113730340A (zh) 一种注射用脂肪酸缓释组合物及其制备方法和应用
US20250040935A1 (en) Fabrication of radiopaque resorbable hydrogel beads via microfluidics for catheter embolization applications
HK1204551B (en) Injectable compositions
ALAEI et al. Preparation of a reservoir type levonorgestrel delivery system using high molecular weight poly L-lactide
RU2548722C1 (ru) Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола
CN116549636A (zh) 一种盐酸氨酮戊酸的专用溶剂及其制备方法和应用
WO2024168024A1 (en) Degarelix organic solvent formulations
OA19845A (en) Injectable composition.
Deadman Biopharmaceutical studies of slow release, subcutaneous polymeric drug delivery systems

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180329

R150 Certificate of patent or registration of utility model

Ref document number: 6317348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250